Rules for regimen creation:

1. LOT1 commences at the start of first core/non-core drug starting from index date. LOT1 comprises all the core/non-core drugs initiated within 21 days of the start of LOT. Three types of regimens may be created:

* Core drugs only
* Non-core drugs only
* Core drugs + Non-core drugs

In case of Core only and Core + Non-core LOTs, a date of last use is identified by considering the latest date of last use (start date + days of supply) of any of the core drugs initiated in the 21 days period. In case of Non-core only LOT, a date of last use is identified by considering the latest date of last use of any of the non-core drugs present in LOT1.

1. If LOT1 comprises Core drugs only or Core + Non-core drugs,
2. LOT1 ends when all core drugs present in LOT1 cease to be used. The use of core drugs in LOT1 or diagnosis codes V58.1 or 99.25 (as explained below) is to be checked from start date of most recent core drug to 60 days post date of latest use of a core drug

(Diagnosis code 99.25 is to be replaced as immediately preceding injectable drug (core/non-core) within 60 days prior to diagnosis code. Diagnosis code V58.1 is to be replaced as immediately preceding drug (core/non-core) within 60 days prior to the diagnosis code. If no such drug is identified within 60 days prior to diagnosis code, the corresponding diagnosis code is ignored. The resultant drug data is to be used for creating LOTs.)

1. If any of the core drugs from LOT1 is identified in a period – from start date of most recent core drug to 60 days post date of latest use of a core drug - update the date of latest use accordingly. Again, core drugs are to be identified until 60 days post updated date of last use, and so on. This step is to be repeated until either no core drugs are identified in the given period or a core drug other than the core drugs present in LOT1 is identified.
2. If no core drug is identified from start date of most recent core drug to 60 days post date of latest use of a core drug, LOT1 ends at date of latest use.
3. If a core drug other that the core drugs present in LOT1 is identified from start date of most recent core drug to 60 days post date of latest use of a core drug, and,

* one or more core drugs from LOT1 overlap with the newly identified core drug which is not present in LOT1, then

1. LOT1 ends one day prior to the beginning of newly identified core drug.
2. LOT2 begins at the start of newly identified core drug. If any of the overlapping core drugs from LOT1 is further identified any time during LOT2, that drug is included in LOT2.
   * none of the core drugs from LOT1 overlaps with the new core drug, end LOT1 at latest use of core drugs. LOT2 begins at the start of newly identified core drug.
3. Non-core drugs identified during or after initial 21 days period will not affect duration of LOT1.
4. If LOT1 comprises non-core drugs only,
5. LOT1 ends when all non-core drugs present in LOT1 cease to be used. The use of non- core drugs in LOT1 or diagnosis codes V58.1 or 99.25 (as explained below) is to be checked from start date of most recent non-core drug to 60 days post date of latest use of a non-core drug.

(Diagnosis code 99.25 is to be replaced as immediately preceding injectable drug (core/non-core) within 60 days prior to diagnosis code. Diagnosis code V58.1 is to be replaced as immediately preceding drug (core/non-core) within 60 days prior to the diagnosis code. If no such drug is identified within 60 days prior to diagnosis code, the corresponding diagnosis code is ignored. The resultant drug data is to be used for creating LOTs.)

1. If any of the non-core drugs from LOT1 is identified in a period – from start date of most recent non-core drug to 60 days post date of latest use of a non-core drug - update the date of latest use accordingly. Again, non-core drugs from LOT1 are to be identified until 60 days post updated date of last use, and so on. This step is to be repeated until either no non-core drugs from LOT1 are identified in that period or a core drug is identified.
2. If no non-core drug from LOT1 is identified from start date of most recent non-core drug to 60 days post date of latest use of a non-core drug, the regimen ends at date of latest use.
3. If a core drug is identified from start date of most recent non-core drug to 60 days post date of latest use of a non-core drug, and,

* one or more non-core drugs from LOT1 overlap with the newly identified core drug, then

1. LOT1 ends one day prior to beginning of the newly identified core drug.
2. LOT2 begins at the start of newly identified core drug.

* none of the non-core drugs from LOT1 overlaps with the newly identified core drug, end LOT1 at latest use of non-core drugs in LOT1. LOT2 begins at the start of newly identified core drug.

1. After the end of an LOT, next LOT can begin,

* at start of earliest core drug post end of LOT.
* at start of earliest non-core drug after 60 days post end of LOT given that no core drug precedes it post end of previous LOT.

1. The regimens, start dates and end dates of further LOTs are to be determined in a similar manner.